On Monday, U.S. stocks dipped, following concerns about Greece continued to weigh.
Health care stocks dipped Monday with the NYSE Health Care Sector Index declining about 0.7% and shares of health care companies in the S&P 500 down about 1.0% as a group.
Details about some major losers from healthcare sector, during Monday’s trade are described below:
22nd Century Group, Inc. (NYSEMKT:XXII), traded in a 52-week range of $0.97 to $6.36, hitting new 52-week low of $0.97, with shares dropped -13.68% at $1.01 in pre-market trade Tuesday, as a plant biotechnology company, declared that the Company filed its 2014 Annual Report on Form 10-K with the U.S. Securities and Exchange Commission. Due to travel plans over the next several days, the Company will be unable to conduct a quarterly conference call this week; instead, 22nd Century will provide a business update for investors on a conference call to be held Wednesday, February 11th at 11:00 AM (EST).
22nd Century Group, Inc. (NYSEMKT:XXII)’s stock volatility for the week is 8.21%, while for the month, it is 10.37%.
22nd Century Group, Inc. (NYSEMKT:XXII), is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be reduced or raised through genetic engineering and plant breeding.
Regulus Therapeutics Inc. (NASDAQ:RGLS), declined -7.24% and settled at $15.64, soon after a biopharmaceutical company, declared that it will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus will ring the Closing Bell.
Where: Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio,
When: Tuesday, February 10, 2015 – 3:45 p.m. to 4:00 p.m. ET.
Regulus Therapeutics Inc. (NASDAQ:RGLS)’s stock volatility for the week is 10.21%, while for the month, it is 8.14%.
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States.
OraSure Technologies, Inc. (NASDAQ:OSUR), dipped nearly -5.11% to $7.70, as OraSure formerly declared its merged financial results for the full-year and fourth quarter ended December 31, 2014.
- The Company exceeded $100 million in annual proceeds for the first time in its history. Merged net proceeds for the year ended December 31, 2014 were $106.5 million, an 8% raise from the comparable period of 2013.
- Merged net proceeds for the fourth quarter of 2014 were $28.7 million, which approximated the level of proceeds stated in the fourth quarter of 2013.
OraSure Technologies, Inc. (NASDAQ:OSUR)’s stock volatility for the week is 7.30%, while for the month, it is 5.04%.
OraSure Technologies, Inc. (NASDAQ:OSUR), is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions.
Johnson & Johnson, (NYSE:JNJ), showed a negative movement of -1.31% to end at $99.78. The stock volatility for the week is 1.50%, while for the month, it is 1.64%. With recent decline, the year-to-date (YTD) performance reflected a -4.58% decline below last year. During the past month the stock lost -6.21%, bringing three-month performance to -7.87% and six-month performance to 0.03%.
Formerly, The Dr. Paul Janssen Award for Biomedical Research recently opens its 2015 call for nominations. This prestigious award recognizes individuals whose scientific research has made, or has the potential to make, noteworthy contributions toward the improvement of human health. Nominations will be accepted until March 15, 2015 at www.pauljanssenaward.com for consideration by an independent selection committee of world renowned scientists. Starting in 2015, the cash prize awarded to the scientist or group of scientists receiving the Award will be raised to $200,000. This raise in the monetary award reflects the growing importance of basic biomedical research, and continued recognition by Johnson & Johnson, (NYSE:JNJ), of excellence in the field.
Johnson & Johnson, (NYSE:JNJ), together with its auxiliaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide.
Abbott Laboratories, (NYSE:ABT), traded in a 52-week range of $36.65 to $46.50, with shares dropped -2.15% at $44.52 in pre-market trade, as Abbott declared that it will present at the Leerink Global Healthcare Conference on Thursday, Feb. 12, 2015. Thomas C. Freyman, executive vice president, finance and chief financial officer, will present at 1:15 p.m. Central time.
Abbott Laboratories, (NYSE:ABT)’s stock volatility for the week is 1.72%, while for the month, it is 1.92%.
Abbott Laboratories, (NYSE:ABT), is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare.
